drugset / Trial / NCT03189706
Study of Chemoimmunotherapy for High-Risk Neuroblastoma
Phase 0
Active not recruiting
48 enrolled
Memorial Sloan Kettering Cancer Center
Y-mAbs Therapeutics · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to find out whether an experimental drug called Hu3F8 can be given with the chemotherapy drugs irinotecan and temozolomide and another drug called GM-CSF. The investigators want to find out if this combination is safe and what effect it has on the participant and the disease.
Timeline
- Start
- 2017-06-12
- Primary completion
- 2027-06
- Completion
- 2027-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Irinotecan | Small molecule | 50 mg/m2 | Intravenous |
| Subject | Naxitamab | Monoclonal antibody | 2.25 mg/kg | Intravenous |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | Oral |
| Subject | sargramostim | Protein / enzyme biologic | 250 ug/m2 | Subcutaneous |